Abstract
We investigated the mechanisms by which transforming growth factor (TGF)-β2 inhibited prolactin mRNA expression in GH3 rat pituitary tumor cells. Maximal inhibition was observed with cells exposed to 5 ng/ml TGF-β2 for 24 hr. Continuous presence of the hormone during the entire period was not necessary because exposure of cells to TGF-β2 for 20 min was sufficient to trigger the same extent of prolactin mRNA inhibition at 24 hr as with its persistent presence. The action of TGF-β2 could be abolished by cycloheximide or EGTA, suggesting the requirement of a newly synthesized protein and extracellular Ca2+. The response of prolactin mRNA to TGF-β2 was inhibited by preincubation of cells with phorbol-12-myristate-13-acetate, which down-regulated protein kinase C (PKC). The activities of both the cytosolic and membrane PKC were significantly reduced at 20 min after TGF-β2 addition, and inhibition continued to 24 hr, the last time point analyzed. However, the ratio of cytosolic to membrane PKC was not altered by TGF-β2. Inhibition of PKC did not require the sustained presence of TGF-β2. In vitro kinase assays of the immunoprecipitated PKC demonstrated that the activities of α, ε, μ, and ζ isozymes were significantly decreased in the TGF-β2-treated cells, whereas that of PKCλ was not affected. Western blotting did not reveal any change in PKCε steady state protein levels, suggesting TGF-β2 inhibits PKC activity through a post-translational mechanism. Our results support that inhibition of PKC activity is an early event mediating TGF-β2-inhibited prolactin mRNA expression in GH3 cells.
Footnotes
-
Send reprint requests to: Dr. Fung-Fang Wang, Institute of Biochemistry, National Yang-Ming University, Shih-Pai, Taipei, Taiwan 11221. E-mail: ffwang{at}ym.edu.tw
-
This work was supported by NSC Grants 83–0420-B010–006 M11 and 85–2331-B010–076 M10 from the National Science Council, Taiwan, Republic of China.
- Abbreviations:
- TGF
- transforming growth factor
- PMA
- phorbol-12-myristate-13-acetate
- PKC
- protein kinase C
- TRH
- thyrotropin releasing hormone
- MAP
- mitogen-activated protein kinase
- MBP
- myelin basic protein
- GAPDH
- glyceraldehyde-3-phosphate dehydrogenase
- GH
- growth hormone
- EGTA
- ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
- HEPES
- 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
- SDS
- sodium dodecyl sulfate
- Received August 25, 1997.
- Accepted March 2, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|